Patient description: The patient is a 24-year-old man who has had type 1 diabetes for 11 years. He presents to the emergency room with hyperglycemia and concern for possible diabetic ketoacidosis after not taking his insulin for 3 days. The patient reports that he is currently homeless and has lost his supply of insulin, syringes, glucometer, and glucose testing supplies. The patient states that at the time of his initial diagnosis with type 1 diabetes he was hospitalized with a glucose value >1000 mg/dL. At the time, he was experiencing polyuria, polydipsia, and polyphagia. He reports that he has been on insulin since the time of his diagnosis, and he has never been prescribed oral agents for diabetes management. Most recently, he has been using insulin glargine 55 units once daily, and insulin aspart sliding scale 3 times daily. The patient has had previous episodes of diabetic ketoacidosis, for which he was hospitalized. With this episode of hyperglycemia, he is not experiencing any nausea, vomiting, or abdominal discomfort, and he appears well. His lab studies showed: A1c: 11.3% Creatinine: 0.9 mg/dL with eGFR >60 mL/min Aspartate aminotransferase (AST): 17 U/L Alanine aminotransferase (ALT): 14 U/L Beta-hydroxybutyrate: 0.1 mmol/L Bicarbonate: 25 mEq/L Anion

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Type 1 Diabetes Diabetic Ketoacidosis Provision of informed consent from participant and all legal representatives prior to any study specific procedures 2. Age: Female and/or male aged >18 years 3. Subject must have type 1 diabetes (as diagnosed clinically) ≥ 12 months 4. HbA1c <10 % 5. Insulin use with an average daily dose between 0.6 0 U/kg administered by insulin pump (CSII) 6. BMI 23.0 to 35.0 kg/m2 minimum weight of 50 kg 7. Women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study as judged by the investigator 8. WOCBP must have a negative serum pregnancy test at screening as well as negative urine tests at follow up visits 9. Women must not be breastfeeding  Target Disease Exclusions 1. History of T2DM (type 2 diabetes mellitus), maturity onset diabetes of young (MODY), pancreatic surgery or chronic pancreatitis 2. Any use of oral hypoglycemic agents within 2 weeks prior to the screening visit 3. History of diabetes ketoacidosis (DKA) within 12 weeks prior to prior to the screening visit 4. History of diabetes insipidus 5. History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia) within 3 months prior to prior to the screening visit 6. Frequent episodes of hypoglycemia as defined by more than one episode requiring assistance, emergency care (paramedics or emergency room care) or glucagon therapy (in children defined as seizure or loss of consciousness) , or more than 2 unexplained episodes of symptomatic hypoglycemia within 3 months prior to the screening visit. An unexplained event is defined as an event that cannot be explained by circumstances such as dietary (e.g. missed meal), strenuous exercise, error in insulin dosing, etc. 7. Hypoglycemic unawareness 8. History of Addison's disease or chronic adrenal insufficiency 2. Physical and Laboratory Test Findings 1. Random C-Peptide >0.5 nmol/l 2. Aspartate aminotransferase (AST) > 2X Upper limit of normal (ULN) 3. Alanine aminotransferase (ALT) > 2X ULN 4. Serum total bilirubin > 2X ULN (except known Gilbert's disease) 5. Creatine kinase (CK) > 3X ULN 6. Estimated GFR (eGFR) by the Modification of Diet in Renal Disease (MDRD) formula ≤ 60 ml/min/1.73m2. The renal function, eGFR will be estimated by the abbreviated MDRD, using laboratory measurements of serum creatinine collected at screening 7. Hemoglobin ≤ 11.0 g/dl (110 g/l) for men; hemoglobin ≤10.0 g/dl (100 g/L) for women. 8. Positive for hepatitis B surface antigen or anti-hepatitis C virus antibody or HIV in patient's history. 9. Abnormal Free T4 Note: abnormal TSH value at screening will be further evaluated for free T4.Subjects with abnormal free T4 values will be excluded. A one-time retest may be allowed, as determined by the Investigator, after a minimum of 6 weeks following the adjustment of thyroid hormone replacement therapy in subject who have had a prior diagnosis of a thyroid disorder and who are currently receiving thyroid replacement therapy. Such cases should be discussed with the Sponsor prior to re-testing. The subject must have all screening procedures and laboratory assessments performed as part of this re-test, and all of these must meet enrolment criteria. The subject's number will, however, remain the same as initially assigned